Irinotecan Hydrochloride Eugia (Uk)

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hydrochloride Eugia (Uk), is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and other colorectal cancers in adult patients.

GNH USA supplies Irinotecan Hydrochloride Eugia (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hydrochloride is used in oncology to target colorectal tumor pathways. It is indicated for the following conditions: - Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy. - Colorectal cancer (advanced): provides disease control in patients with unresectable disease. - Colorectal cancer (adjuvant): used post‑surgery to reduce recurrence risk.

Irinotecan Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Fatigue: generalized tiredness during treatment. - Alopecia: hair loss in some patients. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe diarrhea leading to dehydration. - Intestinal perforation or obstruction. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: rash, bronchospasm, or anaphylaxis. - Bone marrow suppression resulting in anemia or thrombocytopenia.

Before initiating Irinotecan Hydrochloride therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: baseline and periodic LFTs are recommended. - Adjust dose in hepatic impairment: use caution and consider dose reduction. - Caution with prior bowel disease: increased risk of severe diarrhea. - Avoid concurrent strong CYP3A4 inhibitors: may raise drug exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan Hydrochloride interacts with several medications that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase toxicity risk. - UGT1A1 inhibitors (e.g., atazanavir): raise SN‑38 levels and toxicity. - Concurrent myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism. - Warfarin: monitor INR for altered anticoagulation. - Nephrotoxic drugs: watch renal function and adjust dosing if needed.